Sunshine Biopharma (SBFM) Total Current Liabilities (2015 - 2026)

Sunshine Biopharma has reported Total Current Liabilities for 12 years, with the latest figure at $5.9 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities rose 2.01% year-over-year to $5.9 million; the trailing twelve-month figure through Mar 2026 stood at $5.9 million (up 2.01% YoY), and the FY2025 full-year result was $6.4 million, up 2.04% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $5.9 million, down from $6.4 million in the prior quarter.
• The five-year high for Total Current Liabilities was $6.9 million in Q4 2022, with the low at $95234.0 in Q1 2022.
• Historically, Total Current Liabilities has averaged $4.9 million across 5 years, with a median of $5.6 million in 2025.
• The largest YoY upside for Total Current Liabilities was 7497.38% in 2022 against a maximum downside of 88.99% in 2022.
• Sunshine Biopharma's Total Current Liabilities stood at $6.9 million in 2022, then declined by 19.9% to $5.6 million in 2023, then gained by 13.74% to $6.3 million in 2024, then gained by 2.04% to $6.4 million in 2025, then fell by 8.78% to $5.9 million in 2026.
• The last three Total Current Liabilities figures came in at $5.9 million (Q1 2026), $6.4 million (Q4 2025), and $6.7 million (Q3 2025), per Business Quant data.